1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited

3.90
EUR
+0.15
(+4.11%)
23.62BMarket Cap
Mar 30Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.95
1.08
1.35
1.59
1.48
1.68
1.59
1.71
2.07
2.52
- -
Basic EPS, GAAP
0.26
0.28
0.33
0.47
0.44
0.46
0.44
0.55
0.74
0.93
- -
Free Cash Flow per Basic Share
0.17
0.2
0.29
0.5
0.16
0.35
0.41
0.46
0.56
1.05
- -
Dividend per Share
0.42
0.07
- -
0.27
0.71
0.06
0.12
0.11
0.31
0.34
- -
Book Value per Share
0.52
0.79
0.43
2.25
3.02
3.38
3.83
4.35
4.83
5.84
5.84
Tangible Book Value per Share
0.5
0.77
0.41
2.25
3.02
3.38
3.82
4.32
4.79
5.78
5.78
Basic Weighted Avg Shares
5,706
5,706
5,706
5,477
5,876
5,921
5,916
5,925
5,930
5,963
5,967
Sales/Revenue/Turnover
5,433
6,186
7,722
8,683
8,690
9,935
9,382
10,104
12,261
15,028
- -
Operating Margin (%)
32.79
30.57
29.43
32.5
32.57
30.55
29.75
28.1
32.88
36.91
- -
Depreciation Expense
121
138
159
202
233
278
345
366
401
393
- -
Net Income, GAAP
1,476
1,595
1,903
2,557
2,569
2,713
2,584
3,278
4,372
5,555
- -
Effective Tax Rate (%)
18.19
17.45
17.59
14.8
17.09
17.79
12.37
12.97
14.03
15.19
- -
Profit Margin (%)
27.17
25.79
24.64
29.45
29.56
27.31
27.54
32.44
35.66
36.97
- -
Working Capital
1,652
3,190
2,180
11,208
14,596
20,156
23,212
22,020
24,747
31,160
31,160
LT Debt
- -
- -
- -
6
82
3,818
4,362
104
61
48
48
Total Equity
2,974
4,519
2,468
13,044
17,876
20,029
22,647
25,795
28,680
35,364
35,364
Return on Invested Capital (%)
- -
39.45
50.83
30.46
15.01
11.84
9.55
8.57
11.63
14.47
- -
Return on Capital (%)
- -
42.59
54.48
32.95
16.57
13.18
10.36
11.68
14.87
17.3
- -
Return on Common Equity (%)
- -
42.59
54.48
32.96
16.62
14.31
12.11
13.53
16.05
17.35
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
57
58
57
LT Borrowings
- -
- -
- -
LT Finance Leases
61
59
48
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5,934
5,946
6,054
Market Capitalization
95,591
156,612
194,065

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
27,442
30,819
35,555
Cash, Cash Equivalents & STI
23,386
27,121
31,566
Accounts Receivable, Net
3,127
2,734
3,039
Inventories
651
653
609
Total Current Liabilities
2,695
3,601
4,395
Payables & Accruals
- -
- -
- -
ST Debt
57
58
57
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
14.7%
23.31%
Free Cash Flow
- -
51.67%
87.23%
Net Income, GAAP
- -
17.63%
27.07%
Sales/Revenue/Turnover
- -
12.08%
22.57%
Total Cash Common Dividend
- -
36.18%
8.28%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
10,104
2024
- -
- -
12,261
2025
- -
- -
15,028

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.55
2024
- -
- -
0.74
2025
- -
- -
0.93

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.11
2024
- -
- -
0.31
2025
- -
- -
0.34

Company Description

Company Profile APIChatGPT
CEO
Hui Juan Zhong
Full Time Employees
9,347
Sector
Health technology
Industry
Pharmaceuticals: major
Address
287 Xiangke Road Shanghai SH China 201210
IPO Date
Jun 14, 2019
Website
hspharm.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Hansoh Pharmaceutical Group Company Limited (3692.HK) is a leading innovation-driven pharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative drugs targeting oncology, anti-infectives, central nervous system diseases, metabolic diseases, and autoimmunity. The company offers a broad portfolio of products including, in oncology, the innovative drugs Ameile (aumolertinib mesylate tablets) and Hansoh Xinfu (flumatinib mesylate tablets), Pulaile (pemetrexed disodium for injection), Xintai (bortezomib for injection), Xinwei (imatinib mesylate tablets), and Tanneng (fosaprepitant dimeglumine for injection); in anti-infectives, the innovative drugs Hengmu (tenofovir amibufenamide tablets) and Mailingda (morinidazole sodium chloride injection), Zetan (tigecycline for injection), and Hengsen (micafungin sodium for injection); in central nervous system diseases, the innovative drug Xinyue (inebilizumab injections, anti-CD19 mAb), Oulanning (olanzapine oral dose formulations), Ailanning (paliperidone extended-release tablets), and Ameining (agomelatine tablets); and in metabolic diseases, the innovative drug Fulaimei (PEG-loxenatide for injection), Fulaidi (repaglinide tablets), and Fulairui (canagliflozin tablets). Founded in 1995 and headquartered in Shanghai with major operations in Lianyungang and Changzhou in Jiangsu Province, China, the company maintains R&D centers in Shanghai, Lianyungang, Changzhou, and Maryland, USA, and conducts business primarily in China while pursuing global partnerships. Recent developments include the National Medical Products Administration's acceptance of the new drug application for HS-10365 capsules targeting RET fusion-positive non-small cell lung cancer in October 2025, approval of a second indication for Xinyue (inebilizumab injection) for IgG4-related disease in September 2025, and granting Roche an exclusive worldwide license (excluding Greater China) to the investigational CDH17-targeting ADC HS-20110 in October 2025 with potential value up to $1.45 billion; the company also presented positive Phase 2 data for HS-20089 (licensed to GSK) in platinum-resistant ovarian cancer and HS-20093 (licensed to GSK) in sarcomas at ESMO 2025, and reported first-half 2025 revenue of RMB 7,434 million, up 14.3% year-over-year, driven by innovative drugs comprising 82.7% of total revenue.